PTO/SB/26 (10-00)

Approved for use through 10/, 1/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPAR's MENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docker Number (Optional)

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT	036781023.CNUS04
In rc Application of: Benjamin R. Yerxa, et al.	
Application No.: 10/010,055	
Filed: November 9, 2001	
For: Method of Treating Dry Eye Disease With Purinergic Receptor Agonists	
hereby disclaims, except as provided below, the terminal part of the statutory term instant application, which would extend beyond the expiration date of the full stat U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of 15,900,407 The owner hereby agrees that any patent so granted on enforceabe only for and during such period that it and the prior patent are common runs with any patent granted on the instant application and is binding upon the granted on the instant application.	atory term defined in 35 serior Patent No. the instant application shall be only owned. This agreement intee, its successors or
In making the above disclaimer, the owner does not disclaim the terminal p the instant application that would extend to the expiration date of the full statutory 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer: expires for failure to pay a maintenance fee, is held unenforceable, is found competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed claims canceled by a reexamination certificate, is reissued, or is in any manner ter expiration of its full statutory term as presently shortened by any terminal disclaim	term as defined in 35 U.S.C. laimer, in the event that it invalid by a count of under 37 CFR 1 321, has all minated prior to the
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of an organization (e.g., corporation, partnership, university undersigned is empowered to act on behalf of the organization.	, government agen, y, etc), the
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by time or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. The undersigned is an attorney or agent of record. Cluby A Signat. in	rell 1/2/03 Date
Albert P. Halluin(Reg 2 Typed	5,227)/Viola Kurg (Reg. 41,131) or printed name
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card be included on this form. Provide credit card information and authorize	information should not tion on PTO-2038.
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assi m Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	e (owner).

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Parent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Bo Patent Application, Washington, DC 20231.

PTO/SB/25 (10-00) Approved for use through 10% 1/2002, OMB 0651-0031
U.S. Parent and Trademark Office; U.S. DEPAR, MENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 03678 -)023 CNUS04

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION In re Application of: Benjamin R. Yerxa, et al. Application No.: 10/010,055 Filed: November 9, 2001 For: Method of Treating Dry Eye Disease With Purinergic Receptor Agonists percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any parent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 3; U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending , filed on December 19, 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be second Application Number 10/027,520 enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is minding upon In making the above disclaimer, the owner does not disclaim the terminal part of any paterat granted on the grantee, its successors or assigns. the instant application that would extend to the expiration date of the full statutory term as define I in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fce, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canculed by a reexamination ertificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, erc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these intarements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements reay jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of record. Albert P. Halluin(Reg. 25,227)/Viola Kung(Reg. 41,131) Typed or printed name Terminal disclaimer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2638. *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the a signee (owner).

Form PTO/SB/96 may be used for making this statement. See MPEP § 324. Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending up on the needs of the indiv. Itaal case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademan Office, Washington, DC 2003, DO MOT STATE OR COMPLETED FORMS TO THIS ADDRESS. STATE TO A STATE OF THE STATE OR COMPLETED FORMS TO THIS ADDRESS. the amount of time you are required to complete this form should be sent to the Chief Information Officer, C.S. Patont and I rederrint Office, Washington, DC 20231.

20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant C management for Patents. Washington, DC 20231.

PTO/\$B/25 (10-00) App. aved for use through 10/ 1/2002. OMB 0651-0031
U.S. Patent and Tradertark Office; U.S. DEPAR, MENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a aid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION In re Application of: Benjamin R. Yerxa, et al. Application No.: 10/010,055 Filed: November 9, 2001 For: Method of Treating Dry Eye Disease With Purinergic Receptor Agonists percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory tenn of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 3 i U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of my patent granted on pending , filed on October 14, 1998 , of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be second Application Number 09/171,169 enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is minding upon In making the above disclaimer, the owner does not disclaim the terminal part of any pateral granted on the grantee, its successors or assigns. the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expire: for failure to pay 1 maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled b / a reexamination . ertificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government age acy, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these : talements were m de with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements reasy jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of record. Albert P. Halluin(R.:g. 25,227)/Viola K ung(Reg. 41,131) Typed or printed name Terminal disclaimer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit surd information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending up on the needs of the indiv. sual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, 1.5. Patent and Trademan Office, Washington, DC the amount of time you are required to complete this form should be sent to the Chief Information Officer, 1.5. Patent and Trademan Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Comprissioner for Patents, Washington, DC 20231.